| release phenomenon | The increased tonus and hyperirritability of muscle-stretch reflexes which occur following damage of the upper portions of the extrapyramidal system. (05 Mar 2000) |
|---|---|
| melanotropin release-inhibiting hormone | Inhibits synthesis and release of melanotropin. Synonym: melanotropin release-inhibiting hormone. Origin: melanotropin + G. States, stationary, + -in (05 Mar 2000) |
| ryanodine receptor calcium release channel | Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells. (12 Dec 1998) |
| pituitary hormone release inhibiting hormones | Polypeptide hormones produced in the hypothalamus which inhibit the release of pituitary hormones. (12 Dec 1998) |
| msh release-inhibiting hormone | <chemical> An oligopeptide hormone produced in the hypothalamus that inhibits the release of melanocyte-stimulating hormone (msh). Chemical name: Melanostatin (12 Dec 1998) |
| control release suture | Eyeless suture with thread attached to needle such that the two separate when tension is applied to the thread. (05 Mar 2000) |
| prolactin release-inhibiting hormone | <chemical> A polypeptide hormone produced in the hypothalamus that inhibits the release of prolactin. Chemical name: Prolactin release-inhibiting factor (12 Dec 1998) |
| histamine release | The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects. (12 Dec 1998) |
| somatotropin release-inhibiting factor | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| somatotropin release-inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| deliberate release | Generally refers to putting a genetically manipulated organism into field trials. (14 Nov 1997) |
| sustained release tablet | A drug product formulation that provides the required dosage initially and then maintains or repeats it at desired intervals. Synonym: prolonged action tablet, repeat action tablet. (05 Mar 2000) |
| alveolar ventilation | The volume of gas expired from the alveoli to the outside of the body per minute; calculated as the respiratory frequency (f) multiplied by the difference between tidal volume and the dead space (VT -VD); units: ml/min BTPS. (05 Mar 2000) |
| artificial ventilation | Application of mechanically or manually generated pressures, usually positive, to gas(es) in or about the airway as a means of producing gas exchange between the lungs and surrounding atmosphere. Synonym: artificial respiration. (05 Mar 2000) |
| assist-control ventilation | Artificial respiration in which inspiration is produced automatically after a set interval if the person has not already begun to inspire. Compare: assisted ventilation, controlled ventilation. (05 Mar 2000) |